Inclusion Criteria:

• * Pregnant women of any age
• * Diagnosed with narcolepsy or obstructive sleep apnea OR has taken solriamfetol or other wake promoting medications or stimulants during pregnancy
• * Resident of a country where solriamfetol is available for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy or OSA
• * Provides written informed consent to participate in the study
• * Authorization for her HCP(s) to provide data to the registry

Exclusion Criteria:

• * Occurrence of pregnancy outcome prior to first contact with the registry coordination center (RCC)
• * Inclusion of a prior pregnancy in the main analysis population